New! RSV Preventive Antibody (Nirsevimab) Promotion
What is RSV? -Respiratory Syncytial Virus (RSV) is a common virus that causes infections of the respiratory tract. It is one of the leading causes of respiratory illness in infants and young children and can lead to bronchiolitis, pneumonia, and hospitalization, particularly in babies under 1 year of age. -Is Nirsevimab an RSV vaccine? No. Nirsevimab is not a vaccine. It is a long-acting monoclonal antibody that provides immediate protection against RSV after administration, helping reduce the risk of severe RSV disease in infants. -Who is eligible to receive Nirsevimab? Nirsevimab is recommended for newborns and infants under 1 year of age, according to approved indications and the pediatrician's clinical assessment. -How many doses of Nirsevimab are needed? In general, one dose of Nirsevimab provides protection throughout a single RSV season.
14,888 THB / set
New! RSV Preventive Antibody (Nirsevimab) Promotion
Protect Your Baby from RSV from Day One with Preventive Antibody
Respiratory Syncytial Virus (RSV) is one of the leading causes of respiratory tract infections in infants and young children, especially newborns and babies under 1 year of age. RSV infection can lead to bronchiolitis, pneumonia, and hospitalization.
A new preventive option is now available: Nirsevimab, a long-acting monoclonal antibody that helps protect infants against RSV. With just one dose, it provides protection throughout the RSV season and helps reduce the risk of severe RSV disease.
Who Is Eligible?
-
Newborn infants
-
Infants under 1 year of age entering their first RSV season
Benefits of RSV Preventive Antibody (Nirsevimab)
-
Provides protection immediately after administration
-
Only one dose is needed for protection throughout the RSV season
-
Helps reduce the risk of severe RSV infection and hospitalization
Clinical studies (CLEVER Study) demonstrated that Nirsevimab can:
-
Reduce medically attended RSV lower respiratory tract infections by 88%
-
Reduce RSV-related hospitalization by 84.2%
-
Reduce severe RSV disease requiring medical care by 91.7%
Recommended Timing
Administration is recommended before or during the RSV season, which typically occurs between:
June – October each year
Who Should Receive Nirsevimab?
-
Newborn infants
-
Infants under 1 year of age
-
Infants entering the RSV season
-
Infants considered appropriate candidates by a pediatrician
Promotional Price
RSV Preventive Antibody (Nirsevimab)
THB 14,888
**Price includes physician consultation and hospital service fees.
